Time and resource optimization are top-of-mind for many clinical labs working with NGS. As a resource for clinical researchers and labs, we revisit this presentation on panel evaluation.
In this presentation, Cynthia Schandl, MD, PhD and Julie Hirschhorn, PhD evaluate the flexibility, affordability, and ease-of-use of different solid tumor and myeloid panels for NGS testing.
Description
While there are multiple advantages to implementing NGS in the clinical lab, NGS testing has the potential to be both time and resource consuming. Cynthia Schandl, MD, PhD and Julie Hirschhorn, PhD of the Medical University of South Carolina will discuss their process for selection of solid tumor and myeloid panels for evaluation. While keeping clinical relevance in mind, the selection process involved assessing assays for flexibility, affordability, and ease-of-use. This presentation will include an evaluation and discussion of the single-tube Stem-Loop Inhibition Mediated Amplification (SLIMamp®) technology from Pillar Biosciences for detection of variants in solid and myeloid tumors.
